Wang, Yuefan
Lih, Tung-Shing Mamie
Chen, Lijun
Xu, Yuanwei
Kuczler, Morgan D.
Cao, Liwei
Pienta, Kenneth J.
Amend, Sarah R.
Zhang, Hui
Funding for this research was provided by:
National Cancer Institute (U54CA143803, U24CA210985)
U.S. Department of Defense (W81XWH-20-10353)
Article History
Received: 8 December 2021
Accepted: 26 May 2022
First Online: 9 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: KJ Pienta is a consultant for CUE Biopharma, Inc., is a founder and holds equity interest in Keystone Biopharma, Inc., and receives research support from Progenics, Inc. SR Amend also holds equity interest in Keystone Biopharma, Inc. The other authors declare no conflicts of interest.